Nitroglycerin CR Tablet
Description
NITROOT-2.6
Nitroglycerin Controlled Release 2.6 mg Tablets
Division: DIABGLYM
Composition
Each controlled-release tablet contains:
Nitroglycerin IP — 2.6 mg
Excipients — q.s.
Colour: Approved colour used
Dosage form: Controlled-release oral tablet
Product Description
NITROOT-2.6 contains Nitroglycerin Controlled Release 2.6 mg, a long-acting nitrate formulation designed for the prevention and long-term management of chronic stable angina pectoris and ischemic heart disease. The controlled-release formulation provides sustained release of nitroglycerin, helping reduce the frequency of angina attacks, improve exercise tolerance, and decrease myocardial oxygen demand.
Nitroglycerin is a well-established anti-anginal agent widely used in cardiology for patients with chronic coronary artery disease, recurrent angina, post-myocardial infarction ischemia, and long-term nitrate therapy. It works by dilating venous and arterial blood vessels, reducing preload and afterload, and improving coronary blood flow.
NITROOT-2.6 is particularly beneficial for patients initiating long-acting nitrate therapy, those requiring lower-dose nitrate prophylaxis, elderly patients, and individuals requiring sustained symptom control with improved myocardial perfusion.
Technical Knowledge of Nitroglycerin Controlled Release
Nitroglycerin is converted within vascular smooth muscle cells to nitric oxide (NO), which activates guanylate cyclase and increases cyclic guanosine monophosphate (cGMP) levels. Elevated cGMP causes relaxation of vascular smooth muscle, resulting in venous and arterial vasodilation.
The controlled-release formulation allows gradual release of nitroglycerin over an extended period, providing sustained anti-anginal activity while reducing fluctuations in plasma concentration.
Mechanism of Action
Nitroglycerin releases nitric oxide, increases cGMP levels, relaxes vascular smooth muscle, produces venous and arterial vasodilation, reduces preload and afterload, decreases myocardial oxygen demand, and improves coronary blood flow.
Key Benefits
Helps prevent chronic angina attacks
Provides sustained anti-anginal protection
Reduces myocardial oxygen demand
Improves coronary blood flow
Enhances exercise tolerance
Reduces frequency of nitrate use for breakthrough angina
Supports long-term ischemic heart disease management
Suitable for chronic anti-anginal therapy under medical supervision
Clinical Applications
NITROOT-2.6 is commonly prescribed for chronic stable angina pectoris, coronary artery disease, ischemic heart disease, post-myocardial infarction angina prevention, long-term nitrate therapy, prevention of recurrent angina episodes, and patients requiring lower-dose nitrate prophylaxis.
Facts About Nitroglycerin
Nitroglycerin is one of the oldest and most extensively studied anti-anginal medications in cardiovascular medicine. Controlled-release nitrate formulations provide prolonged symptom prevention and improved patient compliance in chronic angina management. The 2.6 mg strength is particularly useful for therapy initiation, dose adjustment, elderly patients, and patients requiring individualized long-acting nitrate therapy. Appropriate dosing schedules are important to minimize nitrate tolerance during long-term therapy.
Key Facts
Long-acting nitrate anti-anginal therapy
Nitroglycerin Controlled Release 2.6 mg for sustained angina prevention
Provides prolonged coronary vasodilation
Reduces myocardial oxygen demand
Improves exercise tolerance in chronic angina
Evidence-based cardiovascular therapy
Quality-assured pharmaceutical formulation
PCD Pharma Franchise Opportunity
NITROOT-2.6 is an excellent product for PCD Pharma Franchise, Cardiology Franchise, and Cardio-Diabetic Franchise across India. The increasing prevalence of coronary artery disease, chronic angina, diabetes, hypertension, and ischemic heart disease creates strong prescription demand and long-term market potential for this formulation.
Why Choose NITROOT-2.6 for PCD Pharma Franchise?
High prescription potential
Strong physician and cardiologist acceptance
Attractive monopoly franchise opportunity
Competitive pricing
Promotional support available
Visual aids and marketing inputs
Consistent product quality
Excellent repeat business potential
Third Party Manufacturing
Chemsroot Pharmaceutical offers Third Party Manufacturing of Nitroglycerin Controlled Release 2.6 mg Tablets with complete manufacturing support for pharmaceutical companies, marketers, exporters, and franchise businesses.
Our Third Party Manufacturing Services Include
Private label manufacturing
Contract manufacturing
Custom brand manufacturing
Loan license manufacturing
DCGI-compliant production
GMP-certified manufacturing
Batch manufacturing documentation
Product registration support
Customized packaging and artwork
Monopoly franchise packaging
Bulk manufacturing capability
Manufacturing Features
Pharmaceutical-grade raw materials
IP/BP/USP quality standards
In-process quality control
Finished product testing
Stability-oriented controlled-release formulation
Controlled-release tablet manufacturing technology
Blister and Alu-Alu packaging options
NITROOT-2.6 from DIABGLYM combines sustained anti-anginal protection, improved coronary perfusion, evidence-based cardiovascular therapy, and high-quality pharmaceutical manufacturing, making it an ideal product for physicians, cardiologists, PCD Pharma Franchise partners, and Third Party Manufacturing clients seeking a reliable Nitroglycerin controlled-release formulation.
